改良型1型糖尿病遗传风险评分(T1D GRS2)的建立与标准化
研究基于6,481例病例和9,247例对照,整合HLA等位基因互作及非HLA位点,构建T1D GRS2并验证。该评分含67个SNP和18种HLA DR-DQ单倍型组合,对全部T1D的AUC为0.92,对早发T1D为0.96。模拟新生儿筛查中效率约为单独HLA分型的两倍,优于现有遗传评分。
要点
- T1D GRS2整合67个SNP和18种HLA DR-DQ单倍型互作,区分T1D的AUC达0.92。
- 早发T1D的区分度更高,AUC为0.96。
- 模拟新生儿筛查中效率约为单独HLA分型的两倍,比现有评分高50%。
核心结论
- 改良的T1D GRS2对成人新发糖尿病分型及新生儿筛查具有高度实用性。
研究设计与样本
- 在1型糖尿病遗传学联盟的6,481例病例和9,247例对照中分析HLA区及全基因组变异。
- 构建T1D GRS2并在UK Biobank中验证,评估其在新生儿筛查和糖尿病分型中的影响。
主要发现
- T1D GRS2使用67个SNP并纳入18种HLA DR-DQ单倍型组合的交互作用。
- T1D GRS2对全部T1D的AUC为0.92(P<0.0001,对比旧评分),对早发T1D的AUC为0.96。
- 模拟新生儿筛查中,T1D GRS2效率约为单独HLA基因分型的两倍,比当前遗传评分在普通人群T1D预测中好50%。
关键数值与推荐
- T1D GRS2包含67个SNP和18种HLA DR-DQ单倍型组合。
- 全部T1D的AUC为0.92,早发T1D的AUC为0.96。
临床怎么用
- 可用于成人新发糖尿病的分型鉴别,辅助区分1型糖尿病。
- 在新生儿筛查研究中预测T1D风险,效率优于单独HLA分型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Previously generated genetic risk scores (GRSs) for type 1 diabetes (T1D) have not captured all known information at non-HLA loci or, particularly, at HLA risk loci. We aimed to more completely incorporate HLA alleles, their interactions, and recently discovered non-HLA loci into an improved T1D GRS (termed the "T1D GRS2") to better discriminate diabetes subtypes and to predict T1D in newborn screening studies. RESEARCH DESIGN AND METHODS: In 6,481 case and 9,247 control subjects from the Type 1 Diabetes Genetics Consortium, we analyzed variants associated with T1D both in the HLA region and across the genome. We modeled interactions between variants marking strongly associated HLA haplotypes and generated odds ratios to create the improved GRS, the T1D GRS2. We validated our findings in UK Biobank. We assessed the impact of the T1D GRS2 in newborn screening and diabetes classification and sought to provide a framework for comparison with previous scores. RESULTS: The T1D GRS2 used 67 single nucleotide polymorphisms (SNPs) and accounted for interactions between 18 HLA DR-DQ haplotype combinations. The T1D GRS2 was highly discriminative for all T1D (area under the curve [AUC] 0.92; P < 0.0001 vs. older scores) and even more discriminative for early-onset T1D (AUC 0.96). In simulated newborn screening, the T1D GRS2 was nearly twice as efficient as HLA genotyping alone and 50% better than current genetic scores in general population T1D prediction. CONCLUSIONS: An improved T1D GRS, the T1D GRS2, is highly useful for classifying adult incident diabetes type and improving newborn screening. Given the cost-effectiveness of SNP genotyping, this approach has great clinical and research potential in T1D.
引用
- Sharp SA, Rich SS, Wood AR, et al. Development and Standardization of an Improved Type 1 Diabetes Genetic Risk Score for Use in Newborn Screening and Incident Diagnosis. Diabetes Care. 2019. PMID: 30655379. doi:10.2337/dc18-1785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。